Viracta Therapeutics Inc

NASDAQ:VIRX  
10.52
-0.25 (-2.32%)
Products

Viracta Therapeutics Says FDA Cleared IND Application For Trial In EBV+ Solid Tumors

Published: 07/21/2021 12:47 GMT
Viracta Therapeutics Inc (VIRX) - Viracta Therapeutics Announces FDA Clearance of Ind Application for Phase 1b/2 Trial in Epstein-barr Virus-positive (ebv+) Solid Tumors.
Viracta Therapeutics - Initiation of Phase 1b/2 Trial is Expected in Second Half of 2021.